As expected, treatment with PrPC-Apt DOA significantly decreased the complex IV activity and tetramethylrhodamine ethyl ester (TMRE)-positive population in CRC cells (Figure 4B,C). The gene discussed is LYPLA2P1; the disease is colorectal carcinoma.